148 related articles for article (PubMed ID: 14719879)
1. An interface for direct analysis of (14)c in nonvolatile samples by accelerator mass spectrometry.
Liberman RG; Tannenbaum SR; Hughey BJ; Shefer RE; Klinkowstein RE; Prakash C; Harriman SP; Skipper PL
Anal Chem; 2004 Jan; 76(2):328-34. PubMed ID: 14719879
[TBL] [Abstract][Full Text] [Related]
2. Open tube combustion method of organic samples for stable carbon isotope analysis.
Velivetskaya TA; Ignatyev AV; Reize MV; Kiyashko SI
Rapid Commun Mass Spectrom; 2007; 21(15):2451-5. PubMed ID: 17610237
[TBL] [Abstract][Full Text] [Related]
3. Microdose study of 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects.
Tozuka Z; Kusuhara H; Nozawa K; Hamabe Y; Ikushima I; Ikeda T; Sugiyama Y
Clin Pharmacol Ther; 2010 Dec; 88(6):824-30. PubMed ID: 21048707
[TBL] [Abstract][Full Text] [Related]
4. Accelerator mass spectrometry analysis of background (14)C-concentrations in human blood: aiming at reference data for further microdosing studies.
Minamimoto R; Hamabe Y; Miyaoka T; Hara T; Yoshida K; Oka T; Inoue T
Ann Nucl Med; 2008 Dec; 22(10):883-9. PubMed ID: 19142707
[TBL] [Abstract][Full Text] [Related]
5. Accelerator mass spectrometry of small biological samples.
Salehpour M; Forsgard N; Possnert G
Rapid Commun Mass Spectrom; 2008 Dec; 22(23):3928-34. PubMed ID: 18980253
[TBL] [Abstract][Full Text] [Related]
6. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.
DeGregorio MW; Dingley KH; Wurz GT; Ubick E; Turteltaub KW
Cancer Chemother Pharmacol; 2006 Feb; 57(3):335-42. PubMed ID: 16047147
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer--fitness for purpose in bioanalysis.
Young GC; Corless S; Felgate CC; Colthup PV
Rapid Commun Mass Spectrom; 2008 Dec; 22(24):4035-42. PubMed ID: 19009519
[TBL] [Abstract][Full Text] [Related]
8. A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry.
Ognibene TJ; Bench G; Vogel JS; Peaslee GF; Murov S
Anal Chem; 2003 May; 75(9):2192-6. PubMed ID: 12720362
[TBL] [Abstract][Full Text] [Related]
9. Quantitating isotopic molecular labels with accelerator mass spectrometry.
Vogel JS; Love AH
Methods Enzymol; 2005; 402():402-22. PubMed ID: 16401517
[TBL] [Abstract][Full Text] [Related]
10. Effective determination of the long-lived nuclide 41Ca in nuclear reactor bioshield concretes: comparison of liquid scintillation counting and accelerator mass spectrometry.
Warwick PE; Croudace IW; Hillegonds DJ
Anal Chem; 2009 Mar; 81(5):1901-6. PubMed ID: 19178149
[TBL] [Abstract][Full Text] [Related]
11. Biological and biomedical (14)C-accelerator mass spectrometry and graphitization of carbonaceous samples.
Chung IM; Kim SH
Analyst; 2013 Jun; 138(12):3347-55. PubMed ID: 23626987
[TBL] [Abstract][Full Text] [Related]
12. Improved isotope ratio measurement performance in liquid chromatography/isotope ratio mass spectrometry by removing excess oxygen.
Hettmann E; Brand WA; Gleixner G
Rapid Commun Mass Spectrom; 2007; 21(24):4135-41. PubMed ID: 18041012
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cAMS for
Lozac'h F; Fahrni S; Maria D; Welte C; Bourquin J; Synal HA; Pearson D; Walles M; Camenisch G
Bioanalysis; 2018 Mar; 10(5):321-339. PubMed ID: 29451392
[TBL] [Abstract][Full Text] [Related]
14. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.
Sarapa N; Hsyu PH; Lappin G; Garner RC
J Clin Pharmacol; 2005 Oct; 45(10):1198-205. PubMed ID: 16172185
[TBL] [Abstract][Full Text] [Related]
15. Accelerator mass spectrometry.
Hellborg R; Skog G
Mass Spectrom Rev; 2008; 27(5):398-427. PubMed ID: 18470926
[TBL] [Abstract][Full Text] [Related]
16. Selective conversion of plasma glucose into CO2 by Saccharomyces cerevisiae for the measurement of 13C abundance by isotope ratio mass spectrometry: proof of principle.
Rembacz KP; Faber KN; Stellaard F
Rapid Commun Mass Spectrom; 2007; 21(19):3169-74. PubMed ID: 17768696
[TBL] [Abstract][Full Text] [Related]
17. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique.
Young G; Ellis W; Ayrton J; Hussey E; Adamkiewicz B
Xenobiotica; 2001; 31(8-9):619-32. PubMed ID: 11569529
[TBL] [Abstract][Full Text] [Related]
18. Automated combustion accelerator mass spectrometry for the analysis of biomedical samples in the low attomole range.
van Duijn E; Sandman H; Grossouw D; Mocking JA; Coulier L; Vaes WH
Anal Chem; 2014 Aug; 86(15):7635-41. PubMed ID: 25033319
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a hydrogen laser vacuum ultraviolet source for photoionization mass spectrometry of pharmaceuticals.
Finch JW; Toerne KA; Schram KH; Denton MB
Rapid Commun Mass Spectrom; 2005; 19(1):15-22. PubMed ID: 15573417
[TBL] [Abstract][Full Text] [Related]
20. Application of accelerator mass spectrometry to macromolecules: preclinical pharmacokinetic studies on a polybisphosphonate.
Salehpour M; Håkansson K; Höglund U; Grahn-Westin A; Nilsson S; Márquez M; Possnert G; Holmberg AR
Rapid Commun Mass Spectrom; 2011 Sep; 25(17):2453-8. PubMed ID: 21818805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
